rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.
![Rocket Pharmaceuticals logo](/files/LOGO/1281895-RCKT.png)
Company profile
Ticker
RCKT, RCKTW
Exchange
Website
CEO
Gaurav Shah
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
INOTEK PHARMACEUTICALS CORP
SEC CIK
Corporate docs
Subsidiaries
Rocket Pharmaceuticals, Ltd. • Rocket Foundation, Inc. • Spacecraft Seven, LLC • Zebrafish Merger Sub II, LLC • Rocket Pharmaceutical, Inc. • Rocket Pharmaceuticals, B.V. • Rocket Pharmaceuticals, GmbH • Rocket Pharmaceuticals UK, Ltd. • Rocket Pharmaceuticals Spain, S.L. ...
RCKT stock data
Latest filings (excl ownership)
8-K
Rocket Pharmaceuticals Provides Regulatory Update on About Leukocyte Adhesion Deficiency-I
28 Jun 24
8-K
Amendments to Articles of Incorporation or Bylaws
20 Jun 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
6 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
17 Apr 24
8-K
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
29 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
Transcripts
Latest ownership filings
4
John Militello
24 Jul 24
144
Notice of proposed sale of securities
22 Jul 24
4
Mark Andrew White
9 Jul 24
144
Notice of proposed sale of securities
8 Jul 24
4
RODERICK WONG
20 Jun 24
4
Elisabeth Bjork
20 Jun 24
4
DAVID P SOUTHWELL
20 Jun 24
4
Naveen Yalamanchi
20 Jun 24
4
Keith Woods
20 Jun 24
4
Fady Ibraham Malik
20 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 36.64 mm | 36.64 mm | 36.64 mm | 36.64 mm | 36.64 mm | 36.64 mm |
Cash burn (monthly) | 6.88 mm | 2.44 mm | 22.46 mm | 22.07 mm | 18.95 mm | 16.18 mm |
Cash used (since last report) | 26.60 mm | 9.43 mm | 86.83 mm | 85.33 mm | 73.27 mm | 62.57 mm |
Cash remaining | 10.04 mm | 27.20 mm | -50.19 mm | -48.69 mm | -36.64 mm | -25.94 mm |
Runway (months of cash) | 1.5 | 11.1 | -2.2 | -2.2 | -1.9 | -1.6 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 185 |
Opened positions | 62 |
Closed positions | 19 |
Increased positions | 51 |
Reduced positions | 41 |
13F shares | Current |
---|---|
Total value | 2.37 tn |
Total shares | 94.02 mm |
Total puts | 107.30 k |
Total calls | 240.50 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
RTW Investments | 17.69 mm | $476.51 bn |
Wellington Management | 9.16 mm | $246.67 bn |
BLK Blackrock | 5.93 mm | $159.75 bn |
Vanguard | 5.37 mm | $144.69 bn |
STT State Street | 4.19 mm | $112.96 bn |
Westfield Capital Management | 3.98 mm | $107.33 bn |
Maverick Capital | 3.89 mm | $104.75 bn |
T. Rowe Price | 2.94 mm | $79.29 mm |
JHG Janus Henderson | 2.61 mm | $70.17 bn |
Tang Capital Partners | 2.53 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Jul 24 | John Militello | Common Stock | Sell | Dispose S | No | No | 23.015 | 812 | 18.69 k | 52,515 |
8 Jul 24 | Mark Andrew White | Common Stock | Sell | Dispose S | No | No | 20.395 | 3,026 | 61.72 k | 72,220 |
13 Jun 24 | Wong Roderick | Stock Option Common Stock | Grant | Acquire A | No | No | 15.04 | 3,325 | 50.01 k | 3,325 |
13 Jun 24 | Wong Roderick | Stock Option Common Stock | Grant | Acquire A | No | No | 22.86 | 23,944 | 547.36 k | 23,944 |
13 Jun 24 | Elisabeth Bjork | Stock Option Common Stock | Grant | Acquire A | No | No | 15.04 | 3,325 | 50.01 k | 3,325 |
13 Jun 24 | Elisabeth Bjork | Stock Option Common Stock | Grant | Acquire A | No | No | 22.86 | 23,944 | 547.36 k | 23,944 |
13 Jun 24 | Southwell David P | Stock Option Common Stock | Grant | Acquire A | No | No | 22.86 | 23,944 | 547.36 k | 23,944 |
News
Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $40
3 Jul 24
Rocket Pharmaceuticals Presents Longer-Term Data Updates From Its Lentiviral Vector Hematology Portfolio At ASGCT
10 May 24
Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $53 Price Target
7 May 24
Rocket Pharmaceuticals Q1 EPS $(0.66) Beats $(0.69) Estimate
6 May 24
Press releases
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
29 May 24
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
10 May 24
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
6 May 24